TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > MR Compatibility and Materials Science

MR Compatibility and Materials Science

Author: James Morrison

Magnetic Resonance Imaging (MRI) is a well-established diagnostic technology. Since its introduction in the early 1980s, it has been widely used and extensively developed. It has many of the capabilities of CT scanning, but without the hazard of ionizing radiation. It also has many advantages in tissue discrimination, lacking in other technologies.

As the name suggests, the technology depends on the magnetic properties (responses) of the body (and medical devices) to produce images. Those responses occur in the presence of a static magnetic field 10,000 times greater than the Earth’s magnetic field. We are all familiar with the movement of a compass needle in the Earth’s magnetic field. So, we can all imagine the implications for an implanted medical device in an MRI machine and even a non-implant device adjacent to the machine.

It is, of course, more complex than the above description implies. There are so many factors associated with MRI technology that it is difficult to know where to begin to describe them. It is sufficient to say that the interactions between the MR environment and medical devices are a multi-dimensional problem. Device complexity does nothing to lessen the scale of this problem. Active devices are extremely complex and require even more factors to be considered.

Medical devices, be they implantable or not, or active or passive, may be labelled for their compatibility with the MR environment. Some devices can be marked: “MR Safe.” These tend to be either plastic or ceramic devices, as will be shortly explained. Other devices will need to be marked: “MR Unsafe.” These tend to be made of ferrous metals. Still, other devices may be able to be marked: “MR Conditional.” For these devices, the MR conditions under which they can be used must be spelt out clearly.

This labelling depends on the following factors:

  • Mechanical forces applied to the medical device by the magnetic fields:
    • Translation (bulk displacement)
    • Torque (twisting)
  • Heating as a result of radiofrequency fields.
  • Image artefacts.
  • Electromagnetic interference (active medical devices only).

Naturally, there are standard test methods for most of these factors, some ASTM, some ISO, some EN. The complexity of the standardization reflects the complexity of the subject.

The key characteristics of a medical device that influence its MR compatibility (apart from its size) are the magnetic susceptibility, electrical conductivity and “Proton content”, and to a much lesser extent, thermal conductivity.

Mechanical forces are due to magnetic susceptibility. Materials are either attracted to or repulsed by a magnetic field. The extent to which this occurs is reflected by the scale and sign of the magnetic susceptibility. The following examples should fit with our common experience and reveal some new things.

Material (Volume)
Magnetic Susceptibility (dimensionless)
Electrical Conductivity (S/m)
Aluminium +2.2×10−5 3.77×107
Acrylic (PMMA) −9.06×10−6 –
Copper −9.63×10−6 5.96×107
Glass −1.128×10−5 10−15 to 10−11
Iron +200 000 107
Nickel +600 1.43×107
Vinyl (PVC) −1.071×10−5 –
Water −9.035×10−6 5×10−4 to 5×10−2
Rubber – 10-14
Teflon (PTFE) – 10−25 to 10−23

 

As is commonly understood, Aluminum and plastics are not attracted to magnets; therefore, the magnitude of the susceptibility is very low. Plastics have a negative susceptibility, which means that they are repulsed magnets. This is never observed in common practice because the magnitude is too low.

The magnitude (and sign) of Iron and Nickel are evident and understood as they are very much attracted to magnets.

Note there are no materials listed that are very negative. Such materials are unfortunately not known to exist. If they were known, they would solve a lot of engineering problems including levitating monorail trains.

It is also of note that magnetic susceptibility has no correlation with other physical characteristics like electrical or thermal conductivity, density, melting temperature, elemental/compound, etc.

This should explain my earlier claim that some polymer or ceramic devices can be labelled as MR Safe. The magnitude of their susceptibility is too low to result in either translation or torque being measurable in the device.

You should also note that the susceptibility for Acrylic is very similar to Copper. The difference is only 6%, and the sign is the same. This means that two otherwise identical devices made of these materials would experience only a 6% difference in mechanical forces applied by the same magnetic field. Similarly, Vinyl and Glass which are only 5% apart, same sign. Given the magnitude of these values: 10-5 – 10-6, the scale of such differences would be undetectable.

As the human body contains a lot of water, the susceptibility of that substance is instructive. The body’s water will be exposed to mechanical forces about the same as an acrylic device, on a per-volume basis, but much less than an Iron device.

ASTM F2052 − 15 Standard Test Method for Measurement of Magnetically Induced Displacement Force on Medical Devices in the Magnetic Resonance Environment relates magnetically induced deflection force to device weight (force due to gravity). It provides a conservative reference point by noting that magnetically induced forces on an implanted device should pose no greater risk than normal daily activity in the Earth’s gravitational field.

It may be entirely appropriate to impute the mechanical force test results of one device to another device, where the materials have similar/same magnetic susceptibility. Depending on the scale of the susceptibility, the device design may not be particularly significant.

RF Heating, on the other hand, is dependent on the electrical conductivity of the object (device) in the moving field. Hence, with reference to the table again, devices that are made of polymers or ceramics, having very low conductivity, simply will not heat up. Conversely, metals are highly conductive of electrons and will heat up.

Thus, the conductivity of the body’s water is also instructive. That water will heat up more than a rubber device, on a per length basis, but much less than a Copper device.

Most medical devices that are evaluated for MR compatibility are smaller than the human body. But clearly, the relative scale of the device needs to be a factor in these considerations. In RF Heating testing, the water-based gel background (“phantom” body) increases in temperature (regardless of the device under test).

It may be entirely appropriate to impute the RF heating test results of one device to another device, where the materials have similar/same electrical conductivity.

Image artefacts are due (mostly) to “Proton deficiency.”

MRI was originally called Nuclear Magnetic Resonance Imaging. The “Nuclear” got dropped for marketing reasons, but it is nuclear in the sense that it is the resonance of the nucleus of the Hydrogen atom (aka the Proton) that was being detected.

Metals, and most ceramics, contain no Hydrogen or Protons, so there is no MR signal from them. They appear as dark areas on MR images. Contrast this with X-ray images, where metals (being radiopaque) cast a bright shadow. Organic materials (tissue & plastics) contain a lot of Hydrogen, as does water. That Hydrogen (or at least the nuclei thereof) resonates nicely, and images are produced. Hence MRI is “better” than CT for soft tissues.

The presence of materials with large susceptibility (metals) often results in distortion in the local static field. Distortion is also due to variations in susceptibility between metal and surrounding tissue (and other device materials), and the object size, shape and orientation with respect to the field.

The resulting “image artefact” is a picture of something that is not there. The diagnostic image will show distorted shapes and shadows that do not represent reality. A good example of this effect can occur with cardiac pacing leads. The device is about 4mm in diameter with a metal conductor overlayed with a silicone insulator and is about 50cm long. As implanted, it does not follow a straight path. At certain places along its length, its image appears about 2cm wide.

This loss of image fidelity is a safety issue, as the artefact can hide important information about the body, and particularly the device/body interface. Radiographers use terms like signal-intensity loss/voids, failure of fat suppression, geometric distortion, and bright pile-up to describe these artefacts.

It may be entirely appropriate to impute the image artefact test results of one device to another device, where the materials have similar/same magnetic susceptibility. But image artefacts are highly dependent on device geometry.

In summary, manufacturers considering MR compatibility validation should carefully examine the materials science aspects of their device (and others legally marketed) before proceeding to testing. It may be possible to justify/substantiate MR labelling positions without the considerable costs of experiments.

Manufacturers may find managing these matters – applying standards and complying with regulations and guidance – to be a challenge. Brandwood CKC experts are available to assist in all levels of medical device safety and compliance. Our experts may also be able to reduce the overall testing burden with our material science expertise, as our experience in understanding the expectation from the regulators globally.

Our team is here to support you, so please reach out to us for guidance and any assistance you require regarding MR Compatibility.

If you would like further information or are in need of support for these systems, please contact us.

Contact us
Related posts
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
2nd June 2022
Medical device software brings new complications around compliance
Medical device software brings new complications around compliance
30th May 2022
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
Recent Blogs
  • Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
    2nd June 2022
  • Medical device software brings new complications around compliance
    30th May 2022
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
Recent News
  • Why collaboration and an Integrated Product Development program are key to successful drug development
    14th June 2022
  • Key Takeaways from the PDA Europe Annex 1 Workshop
    7th June 2022
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Thanks so much for your support over the past 30 days. Your commitment and timely communication have made working with you all a pleasant experience.

    US Biotech
    Senior QA Associate
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for